Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
valine-citrulline linker
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "valine-citrulline linker" in MCE Product Catalog:
97
97 Cited Publications
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
Research Areas:
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
Cat. No.: HY-171265
Synonyms: MRG003
Target:
Research Areas:
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575). Becotatug vedotin can be used for the research of cancer, such as squamous cell carcinomas of the head and neck, nasopharyngeal carcinoma .
Cat. No.: HY-P99829
CAS No.: 1869937-48-3
Synonyms: PF-06647020; ABBV-647; h6M24-vc0101
Research Areas:
Cat. No.: HY-15575S
Purity: 97.56%
Synonyms: MC-Val-Cit-PAB-MMAE-d8; mc-vc-PAB-MMAE-d8
Cat. No.: HY-P990049
CAS No.: 2648260-93-7
Synonyms: JMT-101; MRG003 Antibody
Target:
Research Areas:
Cat. No.: HY-W008064
CAS No.: 133174-15-9
Synonyms: Fmoc-L-citrulline
Target:
Research Areas:
Cat. No.: HY-171572
Research Areas:
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model .
Cat. No.: HY-W190913
CAS No.: 2226472-28-0
Research Areas:
DBCO-PEG4-Val-Cit-PAB-PNP is a linker. DBCO-PEG4-Val-Cit-PAB-PNP conjugates anti-SYT2 monoclonal antibody with MALAT1 gapmer antisense oligonucleotides without inhibiting ASO activity or impairing the binding efficiency of the antibody to SYT2 antigen .
0 Images
Sgc8c-M
Cat. No.: HY-177571
Synonyms: Sgc8c-VcMMAE
Cat. No.: HY-171683
Research Areas:
Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research .
Cat. No.: HY-P990049A
Synonyms: JMT-101 (powder); MRG003 Antibody (powder)
Becotatug (powder) (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug (powder) specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug (powder) enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Becotatug (powder) can be used for research related to non-small cell lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma .
Cat. No.: HY-160756
CAS No.: 2952679-21-7
Research Areas:
Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
Cat. No.: HY-185830
Research Areas:
ADC Control Human IgG1-vcMMAE (DAR8) is an antibody-drug conjugate (ADCs), serving as an isotype control for ADC human IgG1-vcMMAE, and inhibits tubulin polymerization. The antibody moiety of ADC Control Human IgG1-vcMMAE (DAR8) is Human IgG1 kappa, Isotype Control (HY-P99001), while the cytotoxic payload and linker moiety are VcMMAE (HY-15575). ADC Control Human IgG1-vcMMAE can be used in cancer-related research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
